FREE Reports

2007 Ranking List: Japanese Pharmaceutical Companies

Download

2007 Ranking List: Japanese Pharmaceutical Companies 2007 Top 20 Pharma League Japan

To improve the quality of future issues, please send us your comments to This email address is being protected from spambots. You need JavaScript enabled to view it.

This FREE report was prepared by La Merie Business Intelligence to compare and rank Japanese pharmaceutical companies regarding sales, net income, R&D expenses and biologics sales in the fiscal year 2007, ended March 31 2008. The report contains a compilation of the raw data and the sources from which they were retrieved. A total of 28 Japanese companies with pharmaceutical activities were analyzed. Excluded were those Japanese pharmaceutical companies which did not publish in English.

An analysis of the 2007 sales, net income and R&D expenses of Japanese companies with a pharmaceutical business conducted by La Merie Business Intelligence revealed the supremacy of Takeda Pharmaceutical Co over Japanese fellow pharma companies. Takeda not only posted record sales of US$ 12.5 bln in 2007, but also received top net income in absolute figures (US$ 3.3 bln) and as a percentage of sales (26.4 %). The Japanese pharma league is composed of four companies in the group of sales between US$ 6 and 12 bln, three companies in the group between US$ 2 and 6 bln, eight in the group of US$ 1 to 2 bln. The remainder of more than 12 companies have pharma sales of less than US$ 1 bln. The mean year-over-year growth rate was 3.2 % with only Kyowa Hakko posting a double digit sales growth in 2007 over the previous year. Only nine of the analyzed Japanese pharma companies had a net income of more than 10 % of pharma sales. Average R&D expenses of Japanese pharmaceutical companies were 15.7 % of sales. Chugai was the pharma company with the most recombinant biologic products and the highest biologics sales of a Japanese pharmaceutical company in 2007 (US$ 1.29 bln), but Kirin had the highest percentage of biologics sales (83 %) of total pharma sales. The combination of the pharma businesses of Kyowa Hakko and Kirin in 2008 ranked the new organization no.10 on a pro forma basis.

Ranking lists were established for:

  • 2007 Total Sales of Japanese Pharmaceutical Companies
  • 2007 Pharma Only Sales of Japanese Pharmaceutical Companies
  • 2007 R&D Expenses of Japanese Pharmaceutical Companies – sorted by US$ mln
  • 2007 R&D Expenses of Japanese Pharmaceutical Companies – sorted by % of Sales
  • 2007 Net Income of Japanese Pharmaceutical Companies – sorted by US$ mln
  • 2007 Net Income of Japanese Pharmaceutical Companies – sorted by % of Sales
  • 2007 Biologics Sales of Japanese Pharamceutical Companies – sorted by US$ mln
  • 2007 Biologics Sales of Japanese Pharmaceutical Companies – sorted by % of Sales

The following Japanese pharmaceutical companies or Japanese companies with a pharmaceutical business unit were analyzed:

  • Ajinomoto
  • Asahi Kasei
  • Astellas Pharma
  • Chugai
  • Daiichi Sankyo
  • Dainippon Sumitomo Pharma
  • Eisai
  • Japan Tobacco
  • Kaken Pharmaceutical Co
  • Kirin Pharma
  • Kissei
  • Kowa Company
  • Kyorin
  • Kyowa Hakko
  • pro forma: Kyowa Hakko Kirin
  • Meiji Saika Kaisha
  • Mitsubishi Tanabe Pharma
  • Mochida Pharmaceutical Co
  • Nippon Chemiphar
  • Nippon Shinyaku
  • Nissan Chemical Industries
  • ONO Pharmaceutical Co
  • Otsuka Pharmaceutical Co
  • Santen Pharmaceutical Co
  • Shionogi
  • Taishi Toyama Pharmaceutical Co
  • Takeda Pharmaceutical Co
  • Teijin
  • Tsumura

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top